Search
Insulin degludec
go.drugbank.com/drugs/DB09564ApprovedInvestigational[A18561,A18562,A18563,A18564,A174934] If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called … [A18561,A18562,A18563,A18564,A174934] Absorption of glucose into cells allows for its transformation into glycogen or fat for storage.
Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for InjectionProducts: Tresiba® FlexTouch® 100 U/ml Solution for Injection, Tresiba ® FlexTouch® 100 U/ml Solution for InjectionNeisseria meningitidis serogroup B recombinant LP2086 B01 protein variant antigen
go.drugbank.com/drugs/DB10285ApprovedInvestigationalNeisseria meningitidis serogroup b recombinant lp2086 b01 protein variant antigen is a sterile vaccine for intramuscular injection indicated for the active immunization to prevent invasive disease caused … A and one from subfamily B (A05 and B01, respectively).
Mixtures: TRUMENBA SUSPENSION FOR INJECTION IN SINGLE-DOSE PRE-FILLED SYRINGE 0.5MLGadoquatrane
go.drugbank.com/drugs/DB33282Approvedto use the lowest gadolinium dose sufficient to image a patient. … [L63814,L63930] Reduced gadolinium exposure is important for patients requiring repeated lifetime imaging - e.g. for multiple sclerosis, spinal conditions, or cancer surveillance - given clinical guidance
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigational[L64098] The FDA approved rusfertide on August 28, 2026 for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer. … [L64098] It is a synthetic cyclic peptide that blocks the iron transporter ferroportin, reducing the availability of iron for red blood cell production and lowering hematocrit.
Synonyms: Isovaleryl-asp-thr-his-phe-pro-cyclo(cys-ile-lys(palm-gamma-glu)- phe-glu-pro-arg-ser-lys-gly-cys)-lys-nh2Dalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalModifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. … Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073].
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseIodide I-123
go.drugbank.com/drugs/DB09420ApprovedInvestigationalIodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. … Radioactive I-123 in particular is effective for this use as its half-life of approximately 13.13 h (hours) is ideal for the 24-h (hour) iodine uptake test and it has a reduced radiation burden as compared
Insulin icodec
go.drugbank.com/drugs/DB16693ApprovedInvestigational[A264093] These modifications - which cause increased serum albumin binding and attenuated insulin receptor affinity - result in a mean half-life of approximately 196 hours, allowing for once-weekly administration … May 2024 for the same indication.
Benzatropine
go.drugbank.com/drugs/DB00245ApprovedInvestigationalpotency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine. … Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease.
Categories: Ethers of Tropine or Tropine DerivativesProducts: BENZATROPINE PHEBRA SOLUTION FOR INJECTION 2 MG/2 MLAnthralin
go.drugbank.com/drugs/DB11157ApprovedIt is a main active ingredient in topical skin formulations for the treatment of psoriasis. Various formulations of the drug are available, including solutions, foams, and shampoos [L1979]. … therapies for psoriasis [L1935].
Categories: Antipsoriatics for Topical UseTrabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalIt is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. … Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery.
Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexProducts: YONDELIS 1MG FOR INJECTION, YONDELIS Powder for Injection 1mg/vial